FDA ODAC Votes in Favor of Abecma, or idecabtagene vicleucel, in Earlier Lines of Therapy for Triple-Class Exposed Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-odac-abecma-earlier-lines-therapy-triple-class-exposed-multiple-myeloma)